These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 11317529)

  • 41. Comparative pharmacology of oral fluoropyrimidines: a focus on pharmacokinetics, pharmacodynamics and pharmacomodulation.
    Milano G; Ferrero JM; François E
    Br J Cancer; 2004 Aug; 91(4):613-7. PubMed ID: 15280932
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacokinetic evaluation of capecitabine in breast cancer.
    Daniele G; Gallo M; Piccirillo MC; Giordano P; D'Alessio A; Del Giudice A; La Porta ML; Perrone F; Normanno N; De Luca A
    Expert Opin Drug Metab Toxicol; 2013 Feb; 9(2):225-35. PubMed ID: 23301520
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Mechanism and possible biochemical modulation of capecitabine (Xeloda), a newly generated oral fluoropyrimidine].
    Saeki T; Takashima S
    Gan To Kagaku Ryoho; 1999 Mar; 26(4):447-55. PubMed ID: 10097741
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Highlights from: 5-Fluorouracil Drug Management Pharmacokinetics and Pharmacogenomics Workshop; Orlando, Florida; January 2007.
    Clin Colorectal Cancer; 2007 Mar; 6(6):407-22. PubMed ID: 17539192
    [No Abstract]   [Full Text] [Related]  

  • 45. Incorporating oral capecitabine into the treatment of breast cancer. Introduction.
    Seidman AD; Aapro M
    Oncologist; 2002; 7 Suppl 6():1-3. PubMed ID: 12454313
    [No Abstract]   [Full Text] [Related]  

  • 46. [ASCO Annual Meeting 2004, New Orleans. Capecitabine in adjuvant therapy of colorectal carcinoma: first... the evidence].
    Longo F; Mansueto G
    Tumori; 2004; 90(5):14-21. PubMed ID: 15656348
    [No Abstract]   [Full Text] [Related]  

  • 47. The use of capecitabine in cancer: management of the hand foot syndrome.
    Sudoyo AW
    Acta Med Indones; 2005; 37(3):174-6. PubMed ID: 16110178
    [No Abstract]   [Full Text] [Related]  

  • 48. Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts.
    Ishikawa T; Utoh M; Sawada N; Nishida M; Fukase Y; Sekiguchi F; Ishitsuka H
    Biochem Pharmacol; 1998 Apr; 55(7):1091-7. PubMed ID: 9605432
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Transmission of apoptosis in human colorectal tumor cells exposed to capecitabine, Xeloda, is mediated via Fas.
    Ciccolini J; Fina F; Bezulier K; Giacometti S; Roussel M; Evrard A; Cuq P; Romain S; Martin PM; Aubert C
    Mol Cancer Ther; 2002 Sep; 1(11):923-7. PubMed ID: 12481413
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Coming to grips with hand-foot syndrome. Insights from clinical trials evaluating capecitabine.
    Scheithauer W; Blum J
    Oncology (Williston Park); 2004 Aug; 18(9):1161-8, 1173; discussion 1173-6, 1181-4. PubMed ID: 15471200
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A physiologically based pharmacokinetic analysis of capecitabine, a triple prodrug of 5-FU, in humans: the mechanism for tumor-selective accumulation of 5-FU.
    Tsukamoto Y; Kato Y; Ura M; Horii I; Ishitsuka H; Kusuhara H; Sugiyama Y
    Pharm Res; 2001 Aug; 18(8):1190-202. PubMed ID: 11587492
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical pharmacokinetics of capecitabine.
    Reigner B; Blesch K; Weidekamm E
    Clin Pharmacokinet; 2001; 40(2):85-104. PubMed ID: 11286326
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Capecitabine in the treatment of colorectal cancer.
    O'Neill VJ; Cassidy J
    Future Oncol; 2005 Apr; 1(2):183-90. PubMed ID: 16555988
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Novel methods of treatment for colorectal carcinoma: from oral chemotherapy to angiogenesis inhibitors].
    Longo F; Mansueto G
    Tumori; 2006; 92(1):suppl 1-15. PubMed ID: 16683391
    [No Abstract]   [Full Text] [Related]  

  • 55. Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients.
    Di Desidero T; Orlandi P; Fioravanti A; Cremolini C; Loupakis F; Marmorino F; Antoniotti C; Masi G; Lonardi S; Bergamo F; Zagonel V; Falcone A; Bocci G
    Invest New Drugs; 2018 Aug; 36(4):709-714. PubMed ID: 29488048
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [First-line Xeloda (Capecitabine) treatment for advanced and recurrent colorectal cancer].
    Guan ZZ; Liu DG; Yu BM; Wu WQ; Shi D; Zhao Y; Wei YQ; Zou LQ; Wu XD; Zhuang W; Feng FY; Zhang P; Yu SY; Xiong HH; Fu Q; Zheng S; Huang JJ; Wu G; Yang CY; Sun SR; Ruan QL
    Zhonghua Zhong Liu Za Zhi; 2004 Feb; 26(2):119-21. PubMed ID: 15059335
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Granulomatous septal panniculitis associated with capecitabine (Xeloda).
    Dalmau J; Roé E; Puig L; Alomar A
    J Eur Acad Dermatol Venereol; 2008 Jan; 22(1):121-2. PubMed ID: 18181993
    [No Abstract]   [Full Text] [Related]  

  • 58. The rational development of capecitabine from the laboratory to the clinic.
    Pentheroudakis G; Twelves C
    Anticancer Res; 2002; 22(6B):3589-96. PubMed ID: 12552961
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacokinetics of capecitabine (Xeloda) in Japanese and Caucasian patients with breast cancer.
    Reigner B; Watanabe T; Schüller J; Lucraft H; Sasaki Y; Bridgewater J; Saeki T; McAleer J; Kuranami M; Poole C; Kimura M; Monkhouse J; Yorulmaz C; Weidekamm E; Grange S
    Cancer Chemother Pharmacol; 2003 Sep; 52(3):193-201. PubMed ID: 12783206
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Contemporary issues and the potential uses of capecitabine in metastatic breast cancer.
    Barrett-Lee P; Bidard FC; Pierga JY
    Cancer Treat Rev; 2009 Nov; 35(7):582-9. PubMed ID: 19632050
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.